Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL29635996 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL580446 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29379290 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL820421 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL36882 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1260827 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL9221238 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL617185 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1262758 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15493 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | claimed |
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION (GB) | 2026-05-26 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122031432-A | Synergistic tolote Luo Nami transdermal patch and preparation method thereof | 浙江海阁堂医药有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12606536-B2 | Bioactive phenolate ionic complexes | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-04-21 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1039882-A1 | THERAPEUTIC FORMULATION FOR ADMINISTERING TOLTERODINE WITH CONTROLLED RELEASE | Pharmacia & Upjohn Aktiebolag (SE) | 2000-10-04 | — | — | EP | claimed |
| WO-2000027364-A1 | NEW CONTROLLED RELEASE BEAD, A METHOD OF PRODUCING THE SAME AND MULTIPLE UNIT FORMULATION COMPRISING IT | PHARMACIA AB (SE) | 2000-05-18 | — | — | WO | claimed |
| WO-2000012070-A1 | TRANSDERMALLY ADMINISTERED TOLTERODINE AS ANTI-MUSCARINIC AGENT FOR THE TREATMENT OF OVERACTIVE BLADDER | PHARMACIA & UPJOHN AB (SE) | 2000-03-09 | — | — | WO | claimed |
| WO-2000012069-A1 | THERAPEUTIC FORMULATION FOR ADMINISTERING TOLTERODINE WITH CONTROLLED RELEASE | PHARMACIA & UPJOHN AB (SE) | 2000-03-09 | — | — | WO | claimed |
| EP-0924983-A4 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | ABERG GUNNAR (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0927034-A1 | METHOD OF TREATING URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-07-07 | — | — | EP | claimed |
| EP-0924983-A1 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | Aberg, Gunnar (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1998011888-A1 | METHOD OF TREATING URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1998003067-A1 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | ABERG GUNNAR (US) | 1998-01-29 | — | — | WO | claimed |